DGAP-News

WILEX AG: Subsidiary Heidelberg Pharma Signs Option Agreement with Max Delbrück Center

DGAP-News: WILEX AG / Key word(s): Alliance
WILEX AG: Subsidiary Heidelberg Pharma Signs Option Agreement with Max
Delbrück Center

19.09.2016 / 07:17
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE

WILEX AG: Subsidiary Heidelberg Pharma Signs Option Agreement with Max
Delbrück Center

- Agreement covers various BCMA antibodies developed by Max Delbrück
Center

- Heidelberg Pharma starts internal development project for multiple
myeloma based on its proprietary ATAC (Antibody Targeted Amanitin
Conjugates) technology with BCMA antibodies

Munich, Germany, 19 September 2016 - WILEX AG (ISIN DE000A11QVV0 / WL6 /
FWB) today announced that its subsidiary Heidelberg Pharma GmbH signed an
exclusive option agreement with the Max Delbrück Center for Molecular
Medicine in the Helmholtz Association (MDC) in Berlin covering various BCMA
antibodies. Financial details are not disclosed but will not have a
material impact on WILEX' cash guidance.

BCMA (B-cell maturation antigens) is a surface protein that is highly
expressed in multiple myeloma cells and to which the selected antibodies
specifically bind. Scientists of the Max Delbrück Center developed those
BCMA specific antibodies. Heidelberg Pharma has generated several
proprietary ATAC molecules with it and generated comprehensive preclinical
data. Based on these data, Heidelberg Pharma has selected the lead
candidate HDP-101. HDP-101 consists of a BCMA antibody, a specific linker
and the toxin Amanitin. Arrangements for formal non-clinical as well as
clinical development of HDP-101 have been started.

Preclinical data showed that HDP-101 had strong in vitro antitumor activity
and led to complete tumor remission in mouse models for multiple myeloma
even at very low doses. In addition, tolerability studies conducted in
different in vivo models identified a very favourable therapeutic window.
Multiple myeloma is the third most common hematologic cancer and represents
a major unmet medical need where new, more effective therapies are urgently
needed.

Professor Andreas Pahl, Head of Research and Development at WILEX AG and
member of the executive management of Heidelberg Pharma GmbH, said: "We are
delighted to have the opportunity to demonstrate the potential of our ATAC
technology using BCMA antibodies of the Max Delbrück Center. Our early
research with these antibodies has been very promising and we are excited